Hyperuricemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
The symptoms of Hyperuricemia include joints becoming swollen, tender, and red, fever, chills, fatigue and kidney problems, or problems with urination. Predisposing factors include age, family history, and certain medications.
The Hyperuricemia pipeline drugs market research report provides an overview of the Hyperuricemia (Metabolic Disorders) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hyperuricemia (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hyperuricemia (Metabolic Disorders) and features dormant and discontinued projects.
Hyperuricemia Pipeline Drugs Market by Key Targets
The targets of the Hyperuricemia pipeline drugs market are Solute Carrier Family 22 Member 12, Xanthine Dehydrogenase/Oxidase, and Uric Acid.
Hyperuricemia Pipeline Drugs Market, by Targets
For more target insights, download a free report sample
Key Mechanism of Actions in the Hyperuricemia Pipeline Drugs Market
The mechanism of actions of the Hyperuricemia pipeline drugs market are Solute Carrier Family 22 Member 12 Inhibitor, Xanthine Dehydrogenase/Oxidase Inhibitor, and Uric Acid Depletor.
Hyperuricemia Pipeline Drugs Market, by Mechanism of Actions
For more mechanism of action insights, download a free report sample
Key Routes of Administration in the Hyperuricemia Pipeline Drugs Market
The routes of administration in the Hyperuricemia pipeline drugs market are oral, intravenous, intramuscular, intravenous drip, and parenteral.
Hyperuricemia Pipeline Drugs Market, by Routes of Administration
For more routes of administration insights, download a free report sample
Key Molecule Types in the Hyperuricemia Pipeline Drugs Market
The molecule types in the Hyperuricemia pipeline drugs market are small molecule, recombinant enzyme, enzyme, fusion protein, and polymer.
Hyperuricemia Pipeline Drugs Market, by Molecule Types
For more molecule type insights, download a free report sample
Key Companies in the Hyperuricemia Pipeline Drugs Market
Some of the key companies in the Hyperuricemia pipeline drugs market are Tonghua Dongbao Pharmaceutical Co Ltd, Arthrosi Therapeutics Inc, Jiangsu Hengrui Medicine Co Ltd, Nippon Chemiphar Co Ltd, Teijin Pharma Ltd, Allena Pharmaceuticals Inc, Amendment Biomedical (Hangzhou) Research Institute Co Ltd, AstraZeneca Plc, Evopoint Bioscience Co Ltd, and Fochon Pharmaceutical Ltd.
Hyperuricemia Pipeline Drugs Market, by Companies
To know more about the companies, download a free report sample
Hyperuricemia Pipeline Drugs Market Report Overview
Key Targets | Solute Carrier Family 22 Member 12, Xanthine Dehydrogenase/Oxidase, and Uric Acid |
Key Mechanism of Actions | Solute Carrier Family 22 Member 12 Inhibitor, Xanthine Dehydrogenase/Oxidase Inhibitor, and Uric Acid Depletor |
Key Routes of Administration | Oral, Intravenous, Intramuscular, Intravenous Drip, and Parenteral |
Key Molecule Types | Small Molecule, Recombinant Enzyme, Enzyme, Fusion Protein, and Polymer |
Key Companies | Tonghua Dongbao Pharmaceutical Co Ltd, Arthrosi Therapeutics Inc, Jiangsu Hengrui Medicine Co Ltd, Nippon Chemiphar Co Ltd, Teijin Pharma Ltd, Allena Pharmaceuticals Inc, Amendment Biomedical (Hangzhou) Research Institute Co Ltd, AstraZeneca Plc, Evopoint Bioscience Co Ltd, and Fochon Pharmaceutical Ltd |
Scope
This report provides:
- A snapshot of the global therapeutic landscape of Hyperuricemia (Metabolic Disorders).
- Reviews of pipeline therapeutics for Hyperuricemia (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
- Descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- Reviews of key companies involved in Hyperuricemia (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- Evaluation of Hyperuricemia (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- All the dormant and discontinued pipeline projects.
- Reviews of the latest news related to pipeline therapeutics for Hyperuricemia (Metabolic Disorders).
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hyperuricemia (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hyperuricemia (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
Amendment Biomedical (Hangzhou) Research Institute Co Ltd
Arthrosi Therapeutics Inc
AstraZeneca Plc
Evopoint Bioscience Co Ltd
Fochon Pharmaceutical Ltd
FortuneRock (China) Ltd
Fuji Yakuhin Co Ltd
Guangdong East Sunshine Pharmaceutical Co Ltd
Hangzhou Grand Biologic Pharmaceutical Inc
Hinova Pharmaceuticals Co Ltd
InventisBio Inc
J-Pharma Co Ltd
Jiangsu Atom Bioscience and Pharmaceutical Co Ltd
Jiangsu Hengrui Medicine Co Ltd
Nippon Chemiphar Co Ltd
NuBioPharma LLC
PegBio Co Ltd
Shanghai Institute of Biological Products Co Ltd
Shanghai Junshi Bioscience Co Ltd
Shanghai Yingli Pharmaceutical Co Ltd
Shanton Pharma Co Ltd
Stealth Biologics LLC
Teijin Pharma Ltd
Tonghua Dongbao Pharmaceutical Co Ltd
Waterstone Pharmaceuticals (Wuhan) Ltd
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets of the Hyperuricemia pipeline drugs market?
The targets of the Hyperuricemia pipeline drugs market are Solute Carrier Family 22 Member 12, Xanthine Dehydrogenase/Oxidase, and Uric Acid.
-
What are the key mechanism of actions of the Hyperuricemia pipeline drugs market?
The mechanism of actions of the Hyperuricemia pipeline drugs market are Solute Carrier Family 22 Member 12 Inhibitor, Xanthine Dehydrogenase/Oxidase Inhibitor, and Uric Acid Depletor.
-
What are the key routes of administration in the Hyperuricemia pipeline drugs market?
The routes of administration in the Hyperuricemia pipeline drugs market are oral, intravenous, intramuscular, intravenous drip, and parenteral.
-
What are the key molecule types in the Hyperuricemia pipeline drugs market?
The molecule types in the Hyperuricemia pipeline drugs market are small molecule, recombinant enzyme, enzyme, fusion protein, and polymer.
-
Which are the key companies in the Hyperuricemia pipeline drugs market?
Some of the key companies in the Hyperuricemia pipeline drugs market are Tonghua Dongbao Pharmaceutical Co Ltd, Arthrosi Therapeutics Inc, Jiangsu Hengrui Medicine Co Ltd, Nippon Chemiphar Co Ltd, Teijin Pharma Ltd, Allena Pharmaceuticals Inc, Amendment Biomedical (Hangzhou) Research Institute Co Ltd, AstraZeneca Plc, Evopoint Bioscience Co Ltd, and Fochon Pharmaceutical Ltd.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.